Zegbeh Jallah
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
26
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Zegbeh Jallah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $6.06 | +1,550.17% | 2 | Dec 27, 2023 | |
| GLYC GlycoMimetics | Initiates: Overweight | $12 | $0.41 | +2,826.83% | 1 | Dec 22, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $11.70 | +276.07% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $3.90 | - | 5 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $30.00 | -3.33% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $48 | $2.27 | +2,014.54% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $11.11 | +530.06% | 2 | May 12, 2022 | |
| SYRS Syros Pharmaceuticals | Maintains: Buy | $200 → $230 | $2.43 | +9,365.02% | 1 | Sep 23, 2021 | |
| RZLT Rezolute | Initiates: Buy | $21 | $5.44 | +286.03% | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | $120 → $135 | $26.80 | +403.73% | 2 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $132 | $3.89 | +3,293.32% | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 → $6 | $0.96 | +526.63% | 2 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $55 | $11.63 | +372.91% | 1 | Feb 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $2.76 | - | 1 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.03 | +676.70% | 1 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.53 | +3,661.52% | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $6.06
Upside: +1,550.17%
GlycoMimetics
Dec 22, 2023
Initiates: Overweight
Price Target: $12
Current: $0.41
Upside: +2,826.83%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $11.70
Upside: +276.07%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $3.90
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $30.00
Upside: -3.33%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $48
Current: $2.27
Upside: +2,014.54%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $11.11
Upside: +530.06%
Syros Pharmaceuticals
Sep 23, 2021
Maintains: Buy
Price Target: $200 → $230
Current: $2.43
Upside: +9,365.02%
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: $21
Current: $5.44
Upside: +286.03%
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: $120 → $135
Current: $26.80
Upside: +403.73%
Jun 30, 2021
Maintains: Buy
Price Target: $108 → $132
Current: $3.89
Upside: +3,293.32%
Jun 11, 2021
Downgrades: Neutral
Price Target: $10 → $6
Current: $0.96
Upside: +526.63%
Feb 18, 2021
Maintains: Buy
Price Target: $30 → $55
Current: $11.63
Upside: +372.91%
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $2.76
Upside: -
May 13, 2020
Initiates: Buy
Price Target: $8
Current: $1.03
Upside: +676.70%
Dec 18, 2019
Initiates: Buy
Price Target: $20
Current: $0.53
Upside: +3,661.52%